Komori
Chordia Therapeutics (190A) · InitiativeFirst stated

rogocekib Receives FDA Orphan Drug Designation

First written in FY2025-H1. . Latest entry: FY2025-H1.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
US orphan drug designation for rogocekibA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2025-H1First statedAnnual report

    「In January 2025, rogocekib received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA). This designation provides various forms of support, including exemption from application fees at the time of approval, data protection for up to 7 years after approval, and tax incentives.」

    In January 2025, rogocekib received ODD from the FDA and became eligible for support including exemption from approval application fees, data protection for up to 7 years after approval, and tax incentives.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Chordia Therapeutics's next results are scheduled for 2026-10-15. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
rogocekib Receives FDA Orphan Drug Designation | Chordia Therapeutics Inc. (190A) | Komori